Aims Concern about hypotension often leads to withholding of beneficial therapy in patients
with heart failure and reduced ejection fraction (HFrEF). We evaluated the efficacy and …

Abstract Aims In the DAPA-HF trial, the SGLT2 inhibitor dapagliflozin reduced the risk of
worsening heart failure (HF) and death in patients with HF and reduced ejection fraction. We …

Aims We examined the efficacy and safety of dapagliflozin, compared with placebo,
according to aetiology in patients with heart failure (HF) with reduced ejection fraction …

Background The aims of this study were to:(i) report the baseline characteristics of patients
enrolled in the Dapagliflozin And Prevention of Adverse‐outcomes in Heart Failure (DAPA …

Whether the sodium–glucose cotransporter 2 inhibitor dapagliflozin reduces the risk of a
range of morbidity and mortality outcomes in patients with heart failure regardless of ejection …

Background: In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in
Heart Failure), the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the risk of …

Objectives This study assessed the efficacy and safety of dapagliflozin in patients who were
or were not taking sacubitril/valsartan at baseline in the DAPA-HF (Study to Evaluate the …

Background: Many patients with heart failure and reduced ejection fraction (HFrEF) have
chronic kidney disease that complicates pharmacological management and is associated …

Heart failure (HF) continues to be a major global health problem with a notable impact in
terms of morbidity and mortality and so, in consequence, with a large unmet necessity for …

BACKGROUND: Patients with heart failure (HF) have a high burden of symptoms and
physical limitations, regardless of ejection fraction (EF). Whether the benefits of SGLT2 …